Learn6 min read
About Triphala: A Classical Blend
Triphala is a classical blend of three fruits. Here is how the Ayurvedic texts describe it. Educational, not medical advice.
In short
- Triphala is a classical blend of three dried fruits: amalaki, bibhitaki and haritaki.
- Tradition takes the powder (churna) in the evening, stirred into warm water.
- It is an herbal product, so ask your doctor or a qualified practitioner before taking it, especially alongside medicines.
Try this today
Start with the food-first step tonight: an early, light dinner and a glass of warm water.
What is triphala, exactly?
Triphala is not a single herb. It is a blend of the dried fruits of three species, mixed in equal proportions: amalaki (Emblica officinalis), bibhitaki (Terminalia bellirica), and haritaki (Terminalia chebula) (Peterson et al., 2017). The word churna simply means powder, so "triphala churna" is that dried, powdered blend. One of the three fruits — amla (amalaki) — has its own herb page.
Laboratory analyses of the blend report a rich tannin and polyphenol profile, including chebulagic acid, chebulinic acid, gallic acid, and ellagic acid (Bairwa, 2025). In the classical Ayurvedic literature, triphala is described as a cornerstone of gastrointestinal and rejuvenative (rasayana) treatment (Peterson et al., 2017).
That last sentence is the traditional Ayurvedic view. It is not clinical proof. Keep the two categories apart and this whole guide becomes easy to read honestly.
What do the classical texts say about it?
Classical Ayurvedic practice uses triphala for vibandha (constipation) as a mild, non-violent laxative and as a general digestive tonic, a framing summarized in the 2017 peer-reviewed review of the Ayurvedic literature (Peterson et al., 2017).
No direct quotation from Charaka, Sushruta, or Vagbhata appears here, because no source translation was in hand during this writing run. Quoting a classical text without the text in front of the writer is fabrication dressed as scholarship. The review-level summary above is what can be honestly said.
A modern voice section (a named vaidya from a published interview, or a journal case report) is database being updated: none could be sourced and verified this run, and inventing one would fail this publication's audit.
Who should be cautious or skip it?
Short-term trial use was well tolerated. In the 14-day open-label trial, no adverse events were reported and safety laboratory parameters showed no significant changes (Mukherjee et al., 2011). But that was 34 people, 14 days, on a combination product. No long-term daily-use safety trial of triphala churna was found among the sources consulted for this guide.
Beyond that sentence, the sourced safety picture is database being updated. Guidance on pregnancy, on laxative dependence from prolonged use, and on drug interactions requires the pharmacopoeial and regulator safety references (Ministry of Ayush, API, NCCIH), and those pages could not be reached during this writing run. If you are pregnant, nursing, taking medication, or managing a chronic condition, do not self-direct: ask a qualified practitioner.
Sources and details
The research in brief
Triphala is a blend of three dried fruits. The one trial with a dosing regimen used the powder stirred into warm water at night. The one randomized trial for constipation used 3–6 grams of triphala churna nightly. Beyond that, human evidence is thin: one small weight-loss trial, one combination-product trial, and a large body of laboratory work.
More key points
- Triphala is the dried fruit of three species (amalaki, bibhitaki, haritaki); the clinical trials tested the powder (churna), not capsules.
- The constipation randomized trial used 3-6 g of churna at night with lukewarm water (a research dose, not personal advice).
- A 12-week trial reported about 5 kg more weight loss than placebo; a 2025 meta-analysis found −2.4 kg on average with high heterogeneity. Preliminary, not proof.
- Almost everything said about antioxidant, anti-inflammatory, or microbiome effects comes from laboratory and animal studies.
- Short trial use was well tolerated. No long-term daily-use safety trial of triphala churna was found among the sources consulted for this guide.
What forms does triphala come in?
The powder is the form with the evidence. Every human trial cited in this guide used churna, either alone or inside a combination product. The constipation trial used loose triphala churna at 3–6 g nightly (DOAJ-indexed RCT); the 14-day constipation trial used a formula containing triphala extract alongside isabgol husk and senna (Mukherjee et al., 2011).
A 2025 meta-analysis pooled 15 controlled trials of triphala and triphala guggul for weight outcomes (Salehi et al., 2025).
Dosing figures for any form other than the churna tested in the trials are database being updated: the Ayurvedic Pharmacopoeia of India monographs could not be consulted during this writing run, and this guide states no number it cannot source.
Should I take it in the morning or at night?
The constipation trial gave the churna at night, after the evening meal, with lukewarm water (DOAJ-indexed RCT). That is the only timing detail with a trial attached among the trials reviewed for this guide. Related: Triphala Before Bed covers the night-dosing question in more depth.
Morning dosing has no comparative trial evidence. Neither does "before food" versus "after food," nor the classical anupana guidance (what the powder is taken with for which purpose). Those are database being updated until the classical passages and the pharmacopoeial instructions can be checked against actual source texts.
Practical note: because the powder is a mild laxative, the trial's choice of night dosing is the sensible reference point. Everything beyond that is tradition, not evidence.
What has actually been tested in humans?
Less than the internet suggests. Three findings survive a hard look.
Constipation, randomized trial. Adults with constipation received either triphala churna (3–6 g nightly with lukewarm water) or a prescribed dietary module. Both groups showed statistically significant laxative effects on the assessed parameters, with the diet arm performing better on weekly bowel-movement frequency and colic pain (DOAJ-indexed RCT). Note the honesty in that result: the powder worked, but diet worked better on two measures.
Constipation, small open-label trial. A 14-day prospective trial (n=34) tested a proprietary formula containing triphala extract plus isabgol husk and senna. Weekly bowel movements increased and Bristol stool-form scores improved (Mukherjee et al., 2011). Related: Triphala vs. Isabgol compares the two for constipation. Two caveats. This was a combination product, not triphala alone. And three authors were affiliated with Tulip Lab Private Limited, the manufacturer of the tested formulation.
Weight, one trial and one meta-analysis. A 12-week double-blind randomized placebo-controlled trial found triphala-treated subjects lost about 5 kg versus placebo, with lower fasting blood sugar and fasting insulin, as summarized in the 2017 review (Peterson et al., 2017). A 2025 meta-analysis of 15 controlled trials of triphala and triphala guggul found an average weight difference of −2.4 kg versus control, with high heterogeneity (I²=91%) and variable study quality (Salehi et al., 2025). Preliminary signal, not proof.
Dental plaque. Human trials of triphala mouthwash for plaque have been reported. The specific papers could not be verified during this writing run, so the details are database being updated rather than asserted from memory.
What does the traditional literature claim that trials haven't tested?
The 2017 peer-reviewed review catalogues reported antioxidant, anti-inflammatory, immunomodulating, and antibacterial properties of triphala, then states plainly that nearly all of this evidence comes from laboratory and animal studies and that human clinical investigation is needed (Peterson et al., 2017). A 2025 review is more optimistic about triphala's therapeutic potential but still draws mostly on preclinical evidence (Bairwa, 2025).
One example: the 2017 review hypothesizes that triphala polyphenols shift gut microbial populations, promoting Bifidobacteria and Lactobacillus while suppressing less desirable microbes (Peterson et al., 2017). It is a hypothesis from preclinical work. No human trial has confirmed a microbiome-mediated clinical benefit.
For "detoxification" (not a measurable clinical endpoint) and for cancer treatment or prevention, there are no human trials; the reviews list antineoplastic effects strictly among preclinical findings requiring clinical development (Peterson et al., 2017). Treat such claims as unproven.
Frequently asked questions
What is triphala, exactly?
Triphala is a polyherbal powder of three dried fruits in equal proportions: amalaki (Emblica officinalis), bibhitaki (Terminalia bellirica), and haritaki (Terminalia chebula), as described in a 2017 peer-reviewed review. "Triphala churna" is that dried, powdered blend. Laboratory analyses report a rich tannin and polyphenol profile, including chebulagic and chebulinic acids.
How much triphala do the trials use?
The only dosing number with a trial behind it is 3–6 grams of triphala churna taken once daily at night with lukewarm water, from a randomized trial in constipation. Treat it as a research dose, not a personal recommendation. Pharmacopoeial dosing figures for any form other than the churna tested in the trials are database being updated.
Should I take it in the morning or at night?
The constipation trial administered the churna at night after the evening meal with lukewarm water. No published human trial tested morning dosing against night dosing, so any claim that one time is better is database being updated. Classical texts do discuss timing, but those passages could not be verified against a source translation during this writing run.
What has actually been tested in humans?
Three things, all modest: a randomized trial of 3–6 g nightly churna for constipation (both trial arms improved, the diet arm more on some measures); a 14-day open-label trial of a combination product containing triphala extract with isabgol and senna in 34 adults; and a 12-week double-blind trial reporting about 5 kg more weight loss than placebo. Everything else is preclinical.
Who should be cautious or skip it?
Short trial use was well tolerated with no adverse events reported, but no human study has tested long-term daily use. Sourced answers on pregnancy, laxative dependence, and drug interactions are database being updated: the regulator and pharmacopoeial safety references for triphala could not be reached during this writing run, and this guide will not invent them.
Sources
- Peterson et al. 2017, therapeutic uses of triphala in Ayurvedic medicine (J Altern Complement Med)
- Randomized controlled trial of triphala churna vs prescribed diet in vibandha (DOAJ)
- Mukherjee et al. 2011, open-label trial of a triphala-containing formula for constipation (J Ayurveda Integr Med)
- Bairwa 2025, triphala pharmacology review (Int J Physiol Pathophysiol Pharmacol)
- Salehi et al. 2025, meta-analysis of 15 controlled trials of triphala for weight (J Med Nat Prod)
Educational only. This guide is not medical advice. Talk to a qualified practitioner or your doctor before changing your routine, especially if you are pregnant, nursing, managing a health condition, or taking medication.